Company intelligence / Profile preview

AFT Pharmaceuticals

Auckland, Auckland, New Zealandpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~110
Development stage: Commercial

Overview

AFT Pharmaceuticals has successfully developed and commercialized multiple pharmaceutical products, including their flagship product Maxigesic IV, which has been licensed in various international markets including Brazil. They recently announced a partnership with Massey Ventures and Gilles McIndoe to develop a topical treatment for keloid and hypertrophic scarring.

Therapeutic areas: GastroenterologyMetabolic DisordersOphthalmologyImmunologyDermatologyOtherNeurologyInfectious Diseases
Modalities: Pharmaceutical products (specific modalities not detailed)
Industry: Biotech

Drug pipeline

12 assets

Combogesic IV

Approved

11 more assets in the full pipeline.

Request access →

Partnerships

Halex Istar (Brazil)Massey VenturesGilles McIndoe

Beyond the preview

Go deeper on AFT Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFT Pharmaceuticals.

Explore the full profile